Past Events
Ophthalmology Innovation Summit
A Novel Integrin-Regulating Portfoliofor Front and Back of the Eye Diseases
Presented by Vicken Karageozian, M.D.
October 10
Hilton, San Francisco
AAO 2019
Primary Results from Phase 2 Study of Risuteganib (RSG) in Intermediate Dry Age-Related Macular Degeneration (dAMD)
Presented by David S. Boyer, M.D.
October 11
Moscone Center, San Francisco
A Pilot Study to Evaluate the Safety and Exploratory Efficacy of ALG-1007 Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
Presented by Richard L. Lindstrom, M.D.
October 14
Moscone Center, San Francisco (ePoster Discussion)
Safety and Efficacy of Risuteganib in Non-Exudative Age-Related Macular Degeneration
Presented by Glenn J. Jaffe, M.D.
Moscone Center, San Francisco (ePoster)
ESCRS
Safety and Efficacy of a Novel Integrin Inhibitor ALG-1007 Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
Presented by Eric Donnenfeld, M.D.
September 16, 2019
Paris Expo Porte de Versailles, Paris, France
The Retina Society 2019 Annual Meeting
Safety and Efficacy of Risuteganib in Intermediate Non-exudative (Dry) Age-Related Macular Degeneration (AMD): Primary Results from a Phase 2 Study
Presented by David S. Boyer, M.D.
September 12, 2019
The Landmark London, London, UK
EURETINA
Safety and Efficacy of Risuteganib in Non Exudative Age-Related Macular Degeneration: Primary Results from a Phase 2 Study
Presented by Peter K. Kaiser, M.D.
September 8, 2019
Palais des Congrès, Paris, France
